NTRA
Natera·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 4
Bearish signal 2
Consensus Rating "Buy"
Ample Liquidity
High Gross Profit Margin
Significant Net Income Decline
Revenue Beats Expectation
EPS Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About NTRA
Natera, Inc.
A global leader in cell-free DNA testing
13011 McCallen Pass, Building A Suite 100, Austin, TX 78753
--
Natera, Inc., was incorporated in Delaware in January 2007. The company is a diagnostic company with proprietary molecular and bioinformatics technology that is being applied to transform disease management on a global scale. The company's cell-free DNA (CFDNA) technology combines novel molecular analysis methods that reliably measure many information regions across the genome from samples ranging from small to individual cells, as well as statistical algorithms that combine data provided by the wider scientific community to identify genetic variants covering a wide range of serious diseases with high precision and coverage. The company's goal is to make personalized genetic testing and diagnosis part of the standard of care that protects health and inform earlier and more targeted interventions to help achieve longer, healthier lives.
Earnings Call
Q1/2025
Estimate EPS-0.66
Actual EPS-0.5
Estimate Revenue446.67M
Actual Revenue501.80M
Natera's Q1 2025 Earnings Call: Contradictions Surface on Signatera Growth, Reimbursement, and Margins
May 19,2025 06:53
Earnings Decrypt
Earnings Decrypt
Q2/2025
Estimate EPS-0.59
Actual EPS-0.74
Estimate Revenue476.84M
Actual Revenue546.60M
Natera's Q2 2025: Unraveling Contradictions in Signatera Growth, Women's Health Impact, and Japanese ASP Aspirations
Aug 08,2025 07:36
Earnings Decrypt
Earnings Decrypt
Company Financials
EPS
NTRA has released its 2025 Q3 earnings. EPS was reported at -0.64, versus the expected -0.35, missing expectations. The chart below visualizes how NTRA has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
NTRA has released its 2025 Q3 earnings report, with revenue of 592.18M, reflecting a YoY change of 34.66%, and net profit of -87.54M, showing a YoY change of -177.11%. The Sankey diagram below clearly presents NTRA's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
